FCM
CPRX

Fieldview Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Fieldview Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,514
Closed -$325K – 511
2025
Q3 		$325K Sell
16,514
-52,261
-76% -$1.07M 0.05% 321
2025
Q2 		$1.49M Buy
68,775
+50,923
+285% +$1.2M 0.23% 154
2025
Q1 		$433K Buy
+17,852
New +$402K 0.06% 296

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fieldview Capital Management's CPRX Position: Q4 2025 in Review

Fieldview Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q4 2025, closing a stake of 16,514 shares — an estimated $325K sold.

Fieldview Capital Management first reported a position in CPRX in Q1 2025 and held it in 3 quarters. The position peaked at $1.49M in Q2 2025. 373 funds tracked by Wall St. Rank hold CPRX as of Q4 2025.

  • Fieldview Capital Management reported no remaining Catalyst Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Fieldview Capital Management sold 16,514 Catalyst Pharmaceutical shares in Q4 2025, an estimated $325K.
  • Fieldview Capital Management first reported a position in Catalyst Pharmaceutical in Q1 2025 and held it in 3 quarters.
  • Fieldview Capital Management's Catalyst Pharmaceutical position peaked at $1.49M in Q2 2025.
  • 373 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2025.

Based on Fieldview Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.